Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Twist Bioscience Corporation - Common Stock (NQ:TWST)

166.97 -38.03 (-18.55%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Twist Bioscience Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Why Twist Bioscience Stock Skyrocketed This Week ↗
It's plugging into a state-of-the-art research tool developed by a major pharmaceutical company. 
Via The Motley Fool
Topics Artificial Intelligence
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Twist Bioscience (TWST) Q3 2026 Earnings Call Transcript ↗
AI-enabled drug discovery orders drive triple-digit growth as guidance rises. 
Via The Motley Fool
Topics Earnings
Twist Bioscience TWST Q2 Fiscal 2026: Revenue Beat Offset by Wider EPS Miss ↗
Via Chartmill
TWIST BIOSCIENCE CORP (NASDAQ:TWST) Reports Mixed Q1 FY2026 Results with Revenue Beat and Wider Loss ↗
Via Chartmill
News headline image
Twist Bioscience Sees AI Drug Discovery Pipeline Expand ↗
Twist Bioscience (NASDAQ: TWST) stock is up on strong Q3 results and raised guidance. AI drug discovery and NGS businesses show growth. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Twist Bioscience Q3 Earnings Call Highlights ↗
Twist Bioscience (NASDAQ:TWST) reported fiscal 2026 third-quarter revenue of $118.4 million, up 23% from a year earlier, marking its 14th consecutive quarter of growth. The company raised its full-year... 
Via MarketBeat
Topics Earnings
News headline image
Cathie Wood Is Selling This High-Flying Stock. Is It a Buy? ↗
Wood's ETFs sell stocks that have had strong runs to pay for other positions. 
Via The Motley Fool
Topics ETFs
News headline image
The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own ↗
AI's next winners in healthcare could be companies like Eli Lilly and Twist Bioscience. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Twist Bioscience Director Sold 12,000 Shares. Here's What That Means for Investors. ↗
This synthetic DNA specialist, leveraging silicon chip technology, reported a notable insider sale amid a year of strong share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors? ↗
This synthetic biology innovator, known for its DNA-based solutions, reported a notable insider sale amid a year of strong share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Twist Biosciences' (TWST) CEO Sold 16,000 Shares for $1.1 Million ↗
This synthetic biology firm, known for silicon-based DNA synthesis, reported a notable insider sale following strong one-year share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Twist (TWST) Q2 2026 Earnings Call Transcript ↗
Twist (TWST) Q2 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Twist (TWST) Q3 2025 Earnings Transcript ↗
Twist (TWST) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Biotech Beat Nvidia in 2025. Can It Do It Again? ↗
Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cold Chain, High Stakes: A Deep Dive into Azenta’s (AZTA) Life Sciences Transformation
Date: February 5, 2026 Introduction In the high-stakes world of life sciences, the "cold chain" is the invisible backbone of modern medicine. From the development of mRNA vaccines to the emerging... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
TWST Shares Rise 8% — What’s Driving The Rally? ↗
Twist Bioscience Corporation hiked its fiscal year 2026 revenue guidance on the heels of a first quarter earnings report that beat Wall Street estimates. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Twist Bioscience Q1 2026 Earnings Call Transcript ↗
Twist Bioscience Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Twist Bioscience Eyes Profit Turnaround In 2026 After Narrowing Losses ↗
Twist Bioscience reports mixed Q4 earnings with a loss of 45 cents, sales of $99.01 million beating consensus. 
Via Benzinga
News headline image
Twist Bioscience Corp (NASDAQ:TWST) Stock Falls After Q4 Earnings Miss ↗
Twist Bioscience Q4 2025 earnings miss analyst estimates on revenue and EPS, triggering a sharp pre-market stock decline. 
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 14, 2025 ↗
 
Via Benzinga
News headline image
Top Wall Street Forecasters Revamp Twist Bioscience Expectations Ahead Of Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Outlook For Twist Bioscience ↗
 
Via Benzinga
News headline image
This Twist Bioscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Cathie Wood Warns Wall Street Is Missing AI's Biggest Opportunity In Healthcare, Calling It 'Sleeper' Investment Poised For Massive Returns ↗
Cathie Wood, CEO of Ark Invest, believes healthcare is the most profound application of AI and Wall Street is overlooking its potential. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Cathie Wood's Ark Dumps Block Stock Worth $4.8 Million As Bitcoin-Heavy Company Preps Q2 Results ↗
Cathie Wood-led Ark Invest executed a significant trade in Block Inc. (NYSE:XYZ) on Tuesday. 
Via Benzinga
News headline image
Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings ↗
Twist Bioscience beat Q3 revenue estimates, improved gross margins, and narrowed its full-year outlook while forecasting EBITDA breakeven fiscal 2026. 
Via Benzinga
News headline image
Twist Bioscience (TWST) Q3 Profit Surges ↗
Via The Motley Fool
News headline image
Twist Bioscience Corp (NASDAQ:TWST) Reports Mixed Q3 2025 Results with Revenue Miss and EPS Beat ↗
Twist Bioscience reported mixed Q3 2025 results, missing revenue estimates at $96.06M but beating EPS at -$0.47. Shares fell 5% pre-market as investors focused on the sales shortfall. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.